We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Treatment of Vitamin D-Resistant Rickets With 25-Hydroxycholecalciferol

Charles Y. C. Pak, MD; Hector F. DeLuca, PhD; Frederic C. Bartter, MD; Dorothy H. Henneman, MD; Boy Frame, MD; Artemis Simopoulos, MD; Catherine S. Delea
Arch Intern Med. 1972;129(6):894-899. doi:10.1001/archinte.1972.00320060042003.
Text Size: A A A
Published online


The clinical usefulness of 25-hydroxycholecalciferol (calcifediol, 25-HCC) was determined in three patients with vitamin D-resistant rickets (familial x-linked recessive in two, and familial autosomal dominant in one). Two patients responded favorably to calcifediol (4,000 to 5,000 units/day) by the following criteria: They showed a net retention of calcium and phosphorus. Gastrointestinal absorption of calcium increased. Urinary excretion of phosphorus and the endogenous phosphorus clearance decreased. In one patient (with familial hypophosphatemia) serum phosphorus concentration and alkaline phosphatase activity returned towards normal; urinary total hydroxyproline increased and nondialyzable hydroxyproline decreased. The third patient (with familial hypophosphatemia) responded to calcifediol during the first 16 days of treatment with increases in serum phosphorus concentration and in urinary calcium excretion. However, he became resistant to calcifediol as treatment was continued.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.